Cargando…
Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations
BACKGROUND: New cancer treatments, such as immune checkpoint inhibitors (ICIs), can improve survival and health-related quality of life (HRQoL) in patients with cancer. Although long-term monitoring of HRQoL has been shown to improve survival, integration of HRQoL into everyday practice remains poor...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790682/ https://www.ncbi.nlm.nih.gov/pubmed/35014969 http://dx.doi.org/10.2196/25792 |
_version_ | 1784640070439927808 |
---|---|
author | Wilczynski, Ophélie Boisbouvier, Anthony Radoszycki, Lise Cotté, François-Emery Gaudin, Anne-Françoise Lemasson, Hervé |
author_facet | Wilczynski, Ophélie Boisbouvier, Anthony Radoszycki, Lise Cotté, François-Emery Gaudin, Anne-Françoise Lemasson, Hervé |
author_sort | Wilczynski, Ophélie |
collection | PubMed |
description | BACKGROUND: New cancer treatments, such as immune checkpoint inhibitors (ICIs), can improve survival and health-related quality of life (HRQoL) in patients with cancer. Although long-term monitoring of HRQoL has been shown to improve survival, integration of HRQoL into everyday practice remains poorly documented. OBJECTIVE: This study describes experiences and expectations of patients treated with ICIs regarding a discussion of HRQoL with health care professionals (HCPs) in cancer management. METHODS: This cross-sectional study was conducted in an online patient community (Carenity) in France. Patients treated with ICIs for cancer, included between September 2018 and January 2019, completed a questionnaire to assess the involvement of HCP in a discussion of HRQoL and when and what was discussed. RESULTS: Of 82 patients included (mean age: 56.9 years, 95% CI 54.2-59.6; 46 [56%] male; 34 [41%] with lung cancer), 62 (76%) reported discussing HRQoL at least once with HCPs, mainly general practitioners (54/82, 66%), oncologists (53/82, 65%), and hospital nurses (50/82, 61%). Around half (45/82, 55%) of the patients were satisfied with these discussions. Discussions with the oncologist were at the patient’s initiative (34/53, 64%). Discussions occurred primarily during follow-up visits (40/62, 65%), when adverse events occurred (30/62, 48%), and at treatment initiation (27/62, 32%). The most discussed dimensions were symptoms (48/62, 77%) and physical well-being (43/62, 69%). With respect to expectations, 54/82 (66%) patients considered oncologists as the most important HCPs for discussing HRQoL. These discussions were desirable throughout the care pathway, particularly at diagnosis (63/82, 77%) and when treatment was initiated (75/82, 92%) or changed (68/82, 83%). All HRQoL dimensions were considered important to discuss. CONCLUSIONS: With only around half of the patients satisfied with HRQoL discussions, impactful HRQoL integration in clinical practice is critical. According to patients, this integration should involve mainly oncologists and general practitioners, should happen at every step of the care pathway, and should be extended to dimensions that are currently rarely addressed. |
format | Online Article Text |
id | pubmed-8790682 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | JMIR Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-87906822022-02-03 Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations Wilczynski, Ophélie Boisbouvier, Anthony Radoszycki, Lise Cotté, François-Emery Gaudin, Anne-Françoise Lemasson, Hervé J Med Internet Res Original Paper BACKGROUND: New cancer treatments, such as immune checkpoint inhibitors (ICIs), can improve survival and health-related quality of life (HRQoL) in patients with cancer. Although long-term monitoring of HRQoL has been shown to improve survival, integration of HRQoL into everyday practice remains poorly documented. OBJECTIVE: This study describes experiences and expectations of patients treated with ICIs regarding a discussion of HRQoL with health care professionals (HCPs) in cancer management. METHODS: This cross-sectional study was conducted in an online patient community (Carenity) in France. Patients treated with ICIs for cancer, included between September 2018 and January 2019, completed a questionnaire to assess the involvement of HCP in a discussion of HRQoL and when and what was discussed. RESULTS: Of 82 patients included (mean age: 56.9 years, 95% CI 54.2-59.6; 46 [56%] male; 34 [41%] with lung cancer), 62 (76%) reported discussing HRQoL at least once with HCPs, mainly general practitioners (54/82, 66%), oncologists (53/82, 65%), and hospital nurses (50/82, 61%). Around half (45/82, 55%) of the patients were satisfied with these discussions. Discussions with the oncologist were at the patient’s initiative (34/53, 64%). Discussions occurred primarily during follow-up visits (40/62, 65%), when adverse events occurred (30/62, 48%), and at treatment initiation (27/62, 32%). The most discussed dimensions were symptoms (48/62, 77%) and physical well-being (43/62, 69%). With respect to expectations, 54/82 (66%) patients considered oncologists as the most important HCPs for discussing HRQoL. These discussions were desirable throughout the care pathway, particularly at diagnosis (63/82, 77%) and when treatment was initiated (75/82, 92%) or changed (68/82, 83%). All HRQoL dimensions were considered important to discuss. CONCLUSIONS: With only around half of the patients satisfied with HRQoL discussions, impactful HRQoL integration in clinical practice is critical. According to patients, this integration should involve mainly oncologists and general practitioners, should happen at every step of the care pathway, and should be extended to dimensions that are currently rarely addressed. JMIR Publications 2022-01-11 /pmc/articles/PMC8790682/ /pubmed/35014969 http://dx.doi.org/10.2196/25792 Text en ©Ophélie Wilczynski, Anthony Boisbouvier, Lise Radoszycki, François-Emery Cotté, Anne-Françoise Gaudin, Hervé Lemasson. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 11.01.2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included. |
spellingShingle | Original Paper Wilczynski, Ophélie Boisbouvier, Anthony Radoszycki, Lise Cotté, François-Emery Gaudin, Anne-Françoise Lemasson, Hervé Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations |
title | Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations |
title_full | Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations |
title_fullStr | Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations |
title_full_unstemmed | Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations |
title_short | Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations |
title_sort | integrating quality of life in the care pathway of cancer patients undergoing immunotherapy treatment: descriptive, cross-sectional survey of an online patient community's experiences and expectations |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790682/ https://www.ncbi.nlm.nih.gov/pubmed/35014969 http://dx.doi.org/10.2196/25792 |
work_keys_str_mv | AT wilczynskiophelie integratingqualityoflifeinthecarepathwayofcancerpatientsundergoingimmunotherapytreatmentdescriptivecrosssectionalsurveyofanonlinepatientcommunitysexperiencesandexpectations AT boisbouvieranthony integratingqualityoflifeinthecarepathwayofcancerpatientsundergoingimmunotherapytreatmentdescriptivecrosssectionalsurveyofanonlinepatientcommunitysexperiencesandexpectations AT radoszyckilise integratingqualityoflifeinthecarepathwayofcancerpatientsundergoingimmunotherapytreatmentdescriptivecrosssectionalsurveyofanonlinepatientcommunitysexperiencesandexpectations AT cottefrancoisemery integratingqualityoflifeinthecarepathwayofcancerpatientsundergoingimmunotherapytreatmentdescriptivecrosssectionalsurveyofanonlinepatientcommunitysexperiencesandexpectations AT gaudinannefrancoise integratingqualityoflifeinthecarepathwayofcancerpatientsundergoingimmunotherapytreatmentdescriptivecrosssectionalsurveyofanonlinepatientcommunitysexperiencesandexpectations AT lemassonherve integratingqualityoflifeinthecarepathwayofcancerpatientsundergoingimmunotherapytreatmentdescriptivecrosssectionalsurveyofanonlinepatientcommunitysexperiencesandexpectations |